Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06760637 | Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease | PHASE3 | ACTIVE NOT_RECRUITING | 1,035 | — | — | Jan 6, 2025 | Dec 29, 2037 | May 19, 2026 | 463 | United States, Argentina +28 |
| NCT06465368 | A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause | PHASE2 | COMPLETED | 121 | — | — | Jul 11, 2024 | Jul 10, 2025 | Oct 1, 2025 | 51 | United States, Australia +11 |
Time from the date of randomization to the date of the first documentation of objective progressive disease as determined by blinded independent central review (BICR) per RECIST v1.1, or death due to any cause, whichever occurs first
Centrally assessed biopsy
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | PF-07220060 tablet taken by mouth plus Letrozole tablet taken by mouth |
| Arm B | ACTIVE_COMPARATOR | Investigator's Choice of CDK4/6 inhibitor (tablet/capsule) taken by mouth with letrozole tablet taken by mouth |
| Arm A/Experimental/PF-07220060 plus letrozole | EXPERIMENTAL | PF-07220060 given as tablet by mouth twice a day for 14 days. Letrozole given as tablet by mouth once a day for 14 days. |
| Arm B/Control/letrozole | ACTIVE_COMPARATOR | Letrozole given by mouth once a day for 14 days. |
| Name | Type | Description |
|---|---|---|
| PF-07220060 | DRUG | CDK4 inhibitor |
| letrozole | DRUG | endocrine therapy |
| abemaciclib | DRUG | CDK4/6 inhibitor |
| palbociclib | DRUG | CDK4/6 inhibitor |
| ribociclib | DRUG | CDK4/6 inhibitor |
Inclusion Criteria: * Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent. * Documented estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumor * Doc...